Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL14496806 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10361572 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL110914 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2028876 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403831 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4403412 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL329845 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159922-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4013428-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| WO-2021030763-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030763-A1 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018134148-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350910-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | ADORA3 4528/4885ADORA2A 4196/4885ADORA2B 3872/4885 |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | ADORA3 4602/4885ADORA2A 4316/4885ADORA2B 4011/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | ADORA3 4602/4885ADORA2A 4316/4885ADORA2B 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.